Hologic Announces Availability of New Brevera® Breast Biopsy System

Hologic Announces Availability of New Brevera® Breast Biopsy System with CorLumina® Imaging Technology
share Share

Transformational Workflow Solution Offers Real-Time Imaging of Tissue Samples, Resulting in Major Cost and Time Savings


Hologic, Inc. (Nasdaq: HOLX) has announced U.S. commercial availability of the Brevera® breast biopsy system with CorLumina®imaging technology, a groundbreaking real-time breast biopsy and verification system that enhances workflow, improves the patient experience and streamlines the entire biopsy process from start to finish. The first-of-its-kind Brevera system is designed to increase biopsy accuracy with real-time imaging that delivers valuable information at the point of care, enabling clinicians to make informed decisions with confidence.


The Brevera system is the world's first and only breast biopsy solution to combine tissue acquisition, real-time imaging, sample verification and advanced post-biopsy handling in one, integrated system. Designed for 2D and 3D™ breast biopsy, the innovative system allows physicians to perform fast and efficient procedures that save costs and improve the patient experience.1  The new product represents another major advance in Hologic's ongoing efforts to improve patient satisfaction and workflow in the biopsy suite.


Until now, radiologists performing stereotactic breast biopsy procedures to diagnose breast cancer were often required to leave the patient under compression while they moved to another room to image and verify tissue samples. This leads to lengthy procedure times and anxious, uncomfortable patients, and can interrupt facility screening schedules. With the Brevera system, radiologists are able to obtain and image tissue samples in the procedure room in just a few seconds, potentially saving up to 10 minutes per patient and cutting the procedure time by up to 25 percent.2


"We're proud to launch the Brevera system, a major breakthrough for radiologists who, for the first time, will be able to image and verify tissue samples in real-time in the procedure room," said Pete Valenti, Hologic's Division President, Breast and Skeletal Health Solutions. "The Brevera system provides clinicians with more information at the point of care and women with a vastly improved experience, resulting in significant cost and time savings without compromising accuracy or patient health outcomes. The system transforms the stereotactic breast biopsy procedure as we know it, and serves as further proof of Hologic's commitment to better serve the needs of our customers and their patients."


In addition to saving facility resources and physician time during a breast biopsy procedure, the Brevera system's proprietary CorLumina imaging technology helps enhance workflow across multiple departments within a health system. The CorLumina imaging system automates the tissue sample collection and separation process, which allows patient tissue to be sent to pathology with little or no manual handling and protects the integrity of samples. The system also features PACS integration for advanced image sharing and transfer of patient records.


The Brevera system is designed for use with Hologic's Affirm® prone biopsy system, Affirm® breast biopsy guidance system, and MultiCare® Platinum system, as well as most upright and prone systems on the market. For more information please visit: www.BreveraBiopsy.com

Reference

1 3D biopsy only when used with the Affirm breast biopsy system.  
2 2015 Kadence International survey of 200 healthcare professionals.


Source & Image Credit: Hologic


Find More About Hologic

Published on : Thu, 31 Aug 2017



Related Articles
Hologic’s 3Dimensions™ Mammography System now available in Europe

Fastest, Highest Resolution Breast Tomosynthesis System is Designed to Increase Clinical Confidence, Accuracy and Patient Comfort... Read more

Hologic Introduces a More Comfortable Mammogram with the Launch of the SmartCurve™ Breast Stabilization System

93% of Women Surveyed Reported Improved Comfort with the New System* Hologic, Inc . (Nasdaq: HOLX) has announced the... Read more

Hologic Receives FDA 510(k) Clearance to Market SculpSure® for Non-Invasive Body Contouring (Lipolysis) of the Submental Area (Under the Chin)

Patients in Clinical Studies Report 100% Satisfaction Rate   Hologic, Inc. (Nasdaq: HOLX) has announced that the U.S.... Read more

breast biopsy,Hologic,Brevera® Breast Biopsy System,CorLumina® Imaging Technology, Imaging,Peter Valenti, Affirm, prone systems Hologic, Inc. (Nasdaq: HOLX) has announced U.S. commercial availability of the Brevera® breast biopsy system with CorLumina®imaging technology, a groundbreaking real-time breast biopsy and verification system that enhances workflow

No comment


Please login to leave a comment...

Highlighted Products